Navigation Links
38 Cryoablation Studies, Exhibits Presented at National Radiological Society Meeting
Date:12/2/2008

IRVINE, Calif., Dec. 2 /PRNewswire-FirstCall/ -- Endocare, Inc. (Nasdaq: ENDO), an innovative medical device company focused on the development of minimally invasive technologies used by urologists and interventional radiologists for tissue and tumor ablation, announced today that physicians from leading medical institutions including Mayo Clinic, Memorial Sloan-Kettering Cancer Center and the University of Wisconsin School of Medicine, among others, will present a total of 38 scientific papers, posters and educational exhibits related to cryoablation and its effectiveness for treating a wide variety of cancers this week at the 93rd Scientific Assembly and annual meeting of the Radiological Society of North America (RSNA) in Chicago. Cryoablation is a minimally invasive procedure in which tumors are targeted with ultrasound, computed tomography or magnetic resonance imaging guidance and treated by freezing.

The presentations include a 36-month update of a multi-center study that demonstrates the safety, effectiveness and durability of cryoablation as a means of dramatically reducing focal pain for patients whose cancer has spread to their bones. The update on the study, which includes data from 50 of a planned total of 60 patients, is being presented by Matthew Callstrom, M.D., PhD of Mayo Clinic, the lead investigator.

The conference also includes several presentations focused on percutaneous renal, or kidney, cryoablation, the fastest growing cryoablation treatment. Last January the Centers for Medicare and Medicaid Services issued for the first time a payment code for percutaneous renal cryoablation, a procedure that allows physicians to destroy small tumors in the kidney by inserting a probe directly through the skin and freezing the cancerous tissue.

Data were also presented on the effectiveness of cryoablation for treating liver, lung and brain cancers, as well as an immunologic response that occurs in high risk prostate cancer patients treated with cryoablation.

"We are very excited that so many of the world's leading and most creative interventional radiologists are looking to cryoablation as a treatment for bone pain, lung and kidney cancers, in addition to the more traditional use of cryoablation to treat prostate cancer," said Endocare interim CEO Terrence A. Noonan. "The promising RSNA data and the enthusiasm cryoablation is generating among physicians supports our contention that cryoablation is a platform medical technology that can be beneficial to patients with a wide variety of cancers. From a strictly business standpoint, cryoablation for prostate cancer remains a core focus, but this conference demonstrates that there is a broad future for cryoablation as a safe and effective treatment for many forms of cancer."

About Endocare

Endocare, Inc. -- www.endocare.com -- is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

Statements in this press release that are not historical facts are forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, those discussed in "Risk Factors" in the Company's Forms 10-K, Forms 10-Q and other filings with the Securities and Exchange Commission. Such risk factors include, but are not limited to, the following items: the Company has a limited operating history with significant losses and losses may continue in the future; the Company may require additional financing to sustain its operations and without it the Company may not be able to continue operations; the Company's business may be materially and adversely impacted by the loss of the Company's largest customer or the reduction, delay or cancellation of orders from this customer or if this customer delays payment or fails to make payment; the Company may be required to make state and local tax payments that exceed the Company's settlement estimates; uncertainty regarding the ability to convince health care professionals and third party payers of the medical and economic benefits of the Company's products; uncertainty relating to third party reimbursement; the risk that intense competition and rapid technological and industry change may make it more difficult for the Company to achieve significant market penetration; and uncertainty regarding the ability to secure and protect intellectual property rights relating to the Company's technology. The actual results that the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. The Company undertakes no obligation to revise, or update publicly, any forward- looking statements for any reason.

     Investors, Matt Clawson
     Allen & Caron, Inc.
     (949) 474-4300
     matt@allencaron.com
     www.allencaron.com

     Media Contact:
     Len Hall
     Allen & Caron, Inc.
     (949) 474-4300
     len@allencaron.com
     www.allencaron.com

     For Additional Information:
     Terrence A. Noonan, CEO
     Michael R. Rodriguez, CFO
     Endocare, Inc.
     (949) 450-5400
     www.endocare.com

'/>"/>
SOURCE Endocare, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Best Practices Document on Cryoablation Posted on Website of American Urological Association
2. Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity
3. Varian Medical Systems Exhibits a New Version of RapidArc(TM) Radiotherapy Technology and Other Products for Fast, Precise Cancer Treatment
4. Imaging Diagnostic Systems Exhibits at Major Middle East Health Conference
5. Imaging Diagnostic Systems Exhibits CT Laser Breast Imaging Results at Major Italian Multidisciplinary Breast Cancer Meeting
6. Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007
7. Promising Clinical Data on Gen-Probes APTIMA(R) HPV Test Presented at Major European Medical Meeting
8. Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH
9. Interim Analysis of Data from e-HEALING Registry of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at AHA Scientific Sessions 2008
10. Data to Be Presented at 58th Annual Meeting of The American Society of Human Genetics
11. Top-Line Preliminary Data From Phase II/III Study of Cortheras Relaxin in Acute Heart Failure to be Presented in Satellite Symposium at AHA Scientific Sessions 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Eutilex Co. Ltd. ... KRW (US $18.9M) Series A financing. This financing round ... Tech Venture and SNU Bio Angel. This new funding ... billion KRW (US $27.7M) since its founding in 2015. ... bolster the development and commercialization of its immuno-oncology programs, ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... has concluded that “in the setting of previously treated, advanced pancreatic cancer, liquid ... defining the optimal patient population and timing of blood sampling may improve the ...
(Date:12/7/2016)... 2016 /PRNewswire/ - Zenith Capital Corp. ("Zenith" or the "Company") announces ... at the Company,s Annual and Special Meeting. ... place on Thursday, December 15, 2016 at Mount ... EC1040), 4825 Mount Royal Gate SW, Calgary, Alberta ... meeting and management information circular, containing the matters to be ...
(Date:12/7/2016)... , Dec. 7, 2016  Vyriad Inc. announced ... to the company,s Board of Directors. "We ... we build our business and develop our oncolytic viruses ... therapy," said Stephen Russell , MD, PhD, CEO ... , share our vision and passion for making a ...
Breaking Biology Technology:
(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s high-speed AFIS    ... ... DERMALOG is Germany's largest Multi-Biometric supplier: The ... Identification Systems) ... Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification System is part of ...
(Date:11/22/2016)... 2016 According to the new market research report ... Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), ... market is expected to grow from USD 10.74 Billion in 2015 to ... 2016 and 2022. Continue Reading ... ...
(Date:11/19/2016)... 2016 Securus Technologies, a leading provider of ... investigation, corrections and monitoring, announced today that it has ... have an independent technology judge determine who has the ... tech/sophisticated telephone calling platform, and the best customer service. ... most of what we do – which clearly is ...
Breaking Biology News(10 mins):